Thursday October 15, 2020, 5:00 PM – 6:00 PM
Exact Sciences: Biomarkers for Treatment Decisions in Early- and Late-stage Prostate Cancer
Steven Canfield, MD
- What are the relevant clinical endpoints (adverse pathology, metastasis, disease-specific death) for risk stratification in early-stage prostate cancer?
- How do commercial genomic assays for the active surveillance decision compare?
- How do mpMRI and genomic testing improve risk stratification for early-stage disease?
- Utilizing the Oncotype DX AR-V7 Nucleus Detect® assay to personalize treatment decisions for mCRPC patients
Friday November 6, 2020, 12:00 PM – 1:00 PM
Thursday November 12, 2020, 6:00 PM – 7:00 PM